Rates of hospitalization because of an infection.
| Characteristics | cDMARD | TNFi | IFX | ETN | ADA | RTX |
|---|---|---|---|---|---|---|
| Patient-yrs | 3119 | 7162 | 1700 | 2842 | 2620 | 712 |
| No. hospitalizations | 106 | 198 | 53 | 68 | 77 | 37 |
| Length of hospitalization, days, mean (SD) | 6.3 (3.7) | 7.8 (6.7) | 9.5 (7.9) | 7.3 (5.5) | 7.3 (6.7) | 7.9 (6.2) |
| IR/1000 patient-yrs (95% CI) | 34 (28–41) | 28 (24–32) | 31 (23–41) | 24 (19–30) | 29 (23–37) | 52 (37–72) |
| IRR (95% CI) | Ref. | 0.80 (0.58–1.1) | 0.89 (0.58–1.4) | 0.70 (0.47–1.0) | 0.85 (0.58–1.3) | 1.5 (0.90–2.5) |
| aIRR* (95% CI) | Ref. | 1.4 (1.0–1.9) | 1.6 (1.1–2.5) | 1.2 (0.82–1.8) | 1.4 (0.96–2.1) | 2.1 (1.3–3.4) |
| aIRR** (95% CI) | Ref. | 0.9 (0.6–1.4) | 1.2 (0.63–2.3) | 0.84 (0.53–1.3) | 0.98 (0.60–1.6) | 1.1 (0.59–1.9) |
| IRR (95% CI) | — | Ref. | — | — | — | 1.9 (1.2–3.1) |
| aIRR* (95% CI) | — | Ref. | — | — | — | 1.6 (1.0–2.6) |
| aIRR*** (95% CI) | — | Ref. | — | — | — | 1.4 (0.78–2.6) |
↵* Age and sex.
↵** Full model.
↵*** Full model and prior biologic treatments. cDMARD: conventional disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitors; IFX: infliximab; ETN: etanercept; ADA: adalimumab; RTX: rituximab; IR: incidence rates; aIRR: adjusted incidence rate ratios; Ref.: reference group.